Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

8.6K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
8.6K
Glaucoma: Overview01:25

Glaucoma: Overview

1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

920
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
920
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous Sinus Stenting Outcomes in Patients with Papilledema from Secondary Causes of Elevated Intracranial Pressure.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

The association between high-sensitivity C-reactive protein and depression symptom severity among U.S. adults: A multivariable analysis of NHANES data.

Brain, behavior, & immunity - health·2026
Same author

IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.

JAMA neurology·2026
Same author

Risk Factors and Social Determinants of Health for Retinal Artery Occlusion in the National Institutes of Health All of Us Program.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.

Ophthalmology·2026

Related Experiment Video

Updated: Jan 8, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.9K

Neuromyelitis Optica Spectrum Disorder.

Negar Moheb1, John J Chen2

  • 1Department of Neurology, Lehigh Valley Health Network, Allentown, PA.

International Ophthalmology Clinics
|December 22, 2025
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition affecting the optic nerves and spinal cord. Early recognition of its neuro-ophthalmologic signs and prompt immunosuppressive treatment are crucial for managing this distinct condition.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.5K
Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition
06:09

Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition

Published on: August 18, 2023

2.6K

Related Experiment Videos

Last Updated: Jan 8, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.9K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.5K
Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition
06:09

Optic Nerve Sheath Point of Care Ultrasound: Image Acquisition

Published on: August 18, 2023

2.6K

Area of Science:

  • Neuroimmunology
  • Ophthalmology
  • Neurology

Background:

  • Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition distinct from multiple sclerosis (MS) and MOG antibody-associated disease.
  • NMOSD primarily impacts the optic nerves and spinal cord, leading to significant neurological deficits.
  • Atypical optic neuritis (ON) is a common neuro-ophthalmologic manifestation, often causing severe vision loss and bilateral involvement.

Purpose of the Study:

  • To review the characteristic neuro-ophthalmologic findings in NMOSD.
  • To discuss serologic markers and neuroimaging findings associated with NMOSD.
  • To outline current acute and long-term treatment strategies for NMOSD.

Main Methods:

  • Review of characteristic neuro-ophthalmologic findings.
  • Analysis of serologic markers.
  • Evaluation of neuroimaging findings.
  • Discussion of current treatment approaches.

Main Results:

  • NMOSD presents with atypical optic neuritis, distinct from MS-related ON.
  • Characteristic findings include severe vision loss, bilateral optic nerve involvement, and chiasmal inflammation.
  • Early diagnosis and immunosuppressive therapy are critical for managing NMOSD.

Conclusions:

  • Prompt identification of neuro-ophthalmologic signs in NMOSD is essential.
  • Effective management involves both acute and long-term immunosuppressive therapies.
  • Understanding NMOSD's distinct features is vital for appropriate patient care.